The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
about
The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
The prognostic utility of the ...... covery and in-vivo validation.
@ast
The prognostic utility of the ...... covery and in-vivo validation.
@en
type
label
The prognostic utility of the ...... covery and in-vivo validation.
@ast
The prognostic utility of the ...... covery and in-vivo validation.
@en
prefLabel
The prognostic utility of the ...... covery and in-vivo validation.
@ast
The prognostic utility of the ...... covery and in-vivo validation.
@en
P2093
P2860
P50
P1433
P1476
The prognostic utility of the ...... covery and in-vivo validation.
@en
P2093
C Morrissey
D J Lundon
J M Fitzpatrick
S T Aherne
P2860
P2888
P356
10.1186/S12885-017-3100-4
P407
P577
2017-03-01T00:00:00Z
P6179
1084250492